☀️     🌓

Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

NICE osteoporosis guidance unchanged

The National Institute for Health and Clinical Excellence (NICE) has complied with a Court of Appeal ruling and reconsidered the evidence for preventing fractures in patients with osteoporosis.

The original court ruling found the NICE had failed to fully explain its decision on a specific analysis of hip fractures from a research study carried out by the manufacturer of strontium ranelate (Protelos®). The actual recommendations were not questioned by the court. The court ruled that NICE must reconsider and reissue the guidance.

NICE has now reissued the osteoporosis - primary prevention and osteoporosis - secondary prevention including strontium ranelate. The guidelines are unchanged after the review.

Action: Clinicians should be aware that these guidelines are now published and implement any necessary changes to practice.

Share 'NICE osteoporosis guidance unchanged' by emailShare 'NICE osteoporosis guidance unchanged' on FacebookShare 'NICE osteoporosis guidance unchanged' on TwitterShare 'NICE osteoporosis guidance unchanged' on LinkedInShare 'NICE osteoporosis guidance unchanged' on reddit


No Comments to “NICE osteoporosis guidance unchanged”

Leave a Comment

Your email address will not be published. Required fields are marked *

Please be aware that you comment is subject to our Privacy Policy.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Prescribing Advice for GPs is powered by ClassicPress.
Connect to our RSS or Atom Feeds.